| (2R)-N-Hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide;hydrochloride | IC50 | 16.9 [1] |
| (2R)-N-Hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide;hydrochloride | Ki | 43.0 [1] |
| Marimastat | IC50 | 25.0 [1] |
| Marimastat | Ki | 2.4 [1], 8.9 [2], 84.0 [3] |
| Ilomastat | IC50 | 7.0 [1] |
| Ilomastat | Ki | 26.0 [1], 46.0 [2] |
| Prinomastat | IC50 | 0.23 [1], 1.1 [2], 3.5 [3], 4.9 [4] |
| Prinomastat | Ki | 0.27 [1] |
| (2R)-2-[[(2S)-1-[[(2S)-1-Anilino-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-4-phenylbutan-2-yl]amino]propanoic acid | IC50 | 320.0 [1] |
| (2R)-2-[[(2S)-1-[[(2S)-1-Anilino-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-4-phenylbutan-2-yl]amino]propanoic acid | Ki | 467.74 [1] |
| 4-[4-(4-Chloro-phenoxy)-benzenesulfonylmethyl]-tetrahydro-pyran-4-carboxylic acid hydroxyamide | IC50 | 0.3 [1], 7.1 [2] |
| 4-[4-(4-Chloro-phenoxy)-benzenesulfonylmethyl]-tetrahydro-pyran-4-carboxylic acid hydroxyamide | Ki | 9.3 [1] |
| (R)-3-[[[(S)-2-Phenyl-1-(N-methylcarbamoyl)ethyl]amino]carbonyl]-8-phenoxyoctanehydroximic acid | IC50 | 14.0 [1] |
| (R)-3-[[[(S)-2-Phenyl-1-(N-methylcarbamoyl)ethyl]amino]carbonyl]-8-phenoxyoctanehydroximic acid | Ki | 14.0 [1], 14.13 [2], 100.0 [3] |
| Batimastat | IC50 | 0.56 [1], 0.65 [2], 0.73 [3], 0.75 [4], 20.0 [5] |
| Methylamino-phenylalanyl-leucyl-hydroxamic acid | IC50 | 43.0 [1] |
| Methylamino-phenylalanyl-leucyl-hydroxamic acid | Ki | 79.0 [1], 79.43 [2], 89.0 [3] |
| (R)-3-[[[(S)-2-Phenyl-1-(N-methylcarbamoyl)ethyl]amino]carbonyl]-7-(benzyloxy)heptanehydroximic acid | Ki | 15.0 [1], 15.14 [2], 100.0 [3] |
| (R)-3-[[[(S)-2-Phenyl-1-(N-methylcarbamoyl)ethyl]amino]carbonyl]-7-phenoxyheptanehydroximic acid | Ki | 28.0 [1], 28.18 [2], 100.0 [3] |
| Cipemastat | IC50 | 87.0 [1], 527.0 [2] |
| Cipemastat | Ki | 56.0 [1], 527.0 [2] |
| Carbobenzoxyphenylalanine | IC50 | 40000.0 [1], 99000.0 [2] |
| Carbobenzoxyphenylalanine | Ki | 33000.0 [1], 83000.0 [2] |
| Benzyloxycarbonyltryptophan | IC50 | 2500.0 [1], 7500.0 [2] |
| Benzyloxycarbonyltryptophan | Ki | 2100.0 [1], 6300.0 [2] |
| N-Hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)acetamide | IC50 | 4500.0 [1], 5900.0 [2] |
| CID 6914621 | IC50 | 141.0 [1] |
| CID 6914621 | Ki | 141.0 [1] |
| N-Benzyloxycarbonyl-L-tyrosine | IC50 | 22000.0 [1], 24000.0 [2] |
| N-Benzyloxycarbonyl-L-tyrosine | Ki | 18000.0 [1], 20000.0 [2] |
| CID 10370504 | IC50 | 5.89 [1], 5.9 [2] |
| Mmp inhibitor II | IC50 | 18.4 [1], 28.6 [2] |
| Mmp inhibitor II | Ki | 18.0 [1] |
| N-(3-Methoxybenzyl)-4-Oxo-3,4-Dihydroquinazoline-2-Carboxamide | IC50 | 10000.0 [1] |
| (2R)-1-N-Hydroxy-2-N-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-5-N-(2-phenylethyl)pentane-1,2,5-tricarboxamide | Ki | 6.0 [1], 6.03 [2], 100.0 [3] |
| (R)-3-[[[(S)-2-Phenyl-1-(N-methylcarbamoyl)ethyl]amino]carbonyl]-6-(benzyloxy)hexanehydroximic acid | Ki | 42.66 [1], 43.0 [2], 100.0 [3] |
| (2R)-5-N-Benzyl-1-N-hydroxy-2-N-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]pentane-1,2,5-tricarboxamide | Ki | 91.2 [1], 92.0 [2], 100.0 [3] |
| (2R)-2-[[(2S)-1-[[(2S)-1-Anilino-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-4-(4-propylphenyl)butan-2-yl]amino]propanoic acid | Ki | 18.0 [1], 18.2 [2] |
| 5-[(2-Amino-3-phenylpropanoyl)amino]-N-hydroxy-7-methyl-3-(2-methylpropyl)-4-oxooctanamide | IC50 | 16.0 [1], 18.0 [2] |
| 5-[(2-Amino-3-phenylpropanoyl)amino]-N-hydroxy-7-methyl-3-(2-methylpropyl)-4-oxooctanamide | Ki | 13.0 [1], 15.0 [2] |
| Z-D-Trp-OH | IC50 | 86000.0 [1], 287000.0 [2] |
| Z-D-Trp-OH | Ki | 71000.0 [1], 241000.0 [2] |
| (R)-2-(((Benzyloxy)carbonyl)amino)-3-(4-hydroxyphenyl)propanoic acid | IC50 | 432000.0 [1], 450000.0 [2] |
| (R)-2-(((Benzyloxy)carbonyl)amino)-3-(4-hydroxyphenyl)propanoic acid | Ki | 356000.0 [1], 377000.0 [2] |
| 2-((4-Phenoxyphenylsulfonyl)methyl)thiirane | Ki | 15000.0 [1] |
| N-Isobutyl-N-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid | IC50 | 6500.0 [1] |
| N-Isobutyl-N-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid | Ki | 131.83 [1], 133.0 [2] |
| (S)-2-(4'-Bromo-[1,1'-biphenyl]-4-ylsulfonamido)-3-methylbutanoic acid | IC50 | 7.0 [1], 12.0 [2] |
| (S)-2-(4'-Bromo-[1,1'-biphenyl]-4-ylsulfonamido)-3-methylbutanoic acid | Ki | 4.4 [1] |
| 2-[3-(5-Mercapto-[1,3,4]thiadiazol-2YL)-ureido]-N-methyl-3-pentafluorophenyl-propionamide | Ki | 18.0 [1] |
| 2-[3-(5-Mercapto-[1,3,4]thiadiazol-2-YL)-ureido]-N-methyl-3-phenyl-propionamide | Ki | 707.95 [1], 710.0 [2] |
| 3-[(4'-Cyanobiphenyl-4-Yl)oxy]-N-Hydroxypropanamide | IC50 | 25.0 [1], 47.0 [2], 57.0 [3] |
| (2R)-N-[(2S)-3,3-Dimethyl-1-oxo-1-[[(1R)-1-phenylethyl]amino]butan-2-yl]-N'-hydroxy-2-(3-phenylpropyl)butanediamide | IC50 | 8.91 [1], 40.0 [2] |
| (6S,7R,10S)-6-N-Hydroxy-10-N-methyl-7-(2-methylpropyl)-8-oxo-2-oxa-9-azabicyclo[10.2.2]hexadeca-1(14),12,15-triene-6,10-dicarboxamide | IC50 | 7.8 [1] |
| (6S,7R,10S)-6-N-Hydroxy-10-N-methyl-7-(2-methylpropyl)-8-oxo-2-oxa-9-azabicyclo[10.2.2]hexadeca-1(14),12,15-triene-6,10-dicarboxamide | Ki | 32.7 [1] |
| (2R)-N-[(2S)-3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N'-hydroxy-2-(3-phenylpropyl)butanediamide | IC50 | 47.86 [1], 48.0 [2] |
| (2S)-2-[[4-(4-Methoxyphenyl)phenyl]sulfonylamino]-3-methylbutanoic acid | IC50 | 8.0 [1], 1890.0 [2] |
| (2R,3R)-1-[4-[(2-Chloro-4-fluorophenyl)methoxy]phenyl]sulfonyl-N,3-dihydroxy-3-methylpiperidine-2-carboxamide | IC50 | 3.0 [1], 5.0 [2] |
| (2R)-2-[[(2S)-1-[[(2S)-1-Anilino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-4-phenylbutan-2-yl]amino]propanoic acid | Ki | 229.09 [1], 230.0 [2] |
| Benzyl 6-Benzyl-5,7-Dioxo-6,7-Dihydro-5h-[1,3]thiazolo[3,2-C]pyrimidine-2-Carboxylate | IC50 | 30000.0 [1], 100000.0 [2] |
| (2R,3R)-3-(Cyclopentylmethyl)-N-hydroxy-2-[[methyl(methylsulfonyl)amino]methyl]-4-oxo-4-piperidin-1-ylbutanamide | IC50 | 199.53 [1], 200.0 [2] |
| 3-Hydroxy-N-methyl-2-[3-(5-thioxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)-ureido]-propionamide | Ki | 30902.95 [1], 31000.0 [2] |
| N-Methyl-2-[3-(5-thioxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)-ureido]-acetamide | Ki | 165958.69 [1], 166000.0 [2] |
| N-Hydroxy-1-(4-methoxyphenyl)sulfonylpiperazine-2-carboxamide | IC50 | 48.0 [1] |
| (3R)-2-[Ethoxy-(4-methoxyphenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide | Ki | 5.2 [1] |
| Tert-butyl (6S,9R,10S)-10-(hydroxycarbamoyl)-6-(methylcarbamoyl)-9-(2-methylpropyl)-8-oxo-1,7-diazacyclotridecane-1-carboxylate | Ki | 1.0 [1], 3.0 [2] |
| (3S)-N-Hydroxy-4-(4-methoxyphenyl)sulfonyl-2,2-dimethyl-1,1-dioxo-1,4-thiazepane-3-carboxamide | IC50 | 6.9 [1], 6.92 [2] |
| (6S,7S)-N-Hydroxy-6-[(4-phenylpiperazin-1-yl)carbonyl]-5-azaspiro[2.5]octane-7-carboxamide | IC50 | 5000.0 [1] |
| (2R)-N-[(2S)-1-(Benzhydrylamino)-3,3-dimethyl-1-oxobutan-2-yl]-N'-hydroxy-2-(3-phenylpropyl)butanediamide | IC50 | 47.86 [1], 48.0 [2] |
| (S)-N-Hydroxy-4-(4-methoxyphenylsulfonyl)-2,2-dimethyl-1,4-thiazepane-3-carboxamide | IC50 | 0.7 [1], 0.71 [2] |
| (R)-3-[[[(S)-2-Phenyl-1-(N-methylcarbamoyl)ethyl]amino]carbonyl]-7-hydroxyheptanehydroximic acid | Ki | 2187.76 [1], 2200.0 [2] |
| (R)-3-[[[(S)-2-Phenyl-1-(N-methylcarbamoyl)ethyl]amino]carbonyl]-8-hydroxyoctanehydroximic acid | Ki | 426.58 [1], 430.0 [2] |
| (2R)-1-N-Hydroxy-2-N-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-5-N-propylpentane-1,2,5-tricarboxamide | Ki | 360.0 [1], 363.08 [2] |
| (2R)-N-[(2S)-3-Cyclohexyl-1-oxo-1-(2-phenylethylamino)propan-2-yl]-N'-hydroxy-2-(3-phenylpropyl)butanediamide | Ki | 8.3 [1] |
| (2S)-2-[[(2S)-2-[[(2R)-2-Aminopropanoyl]amino]-4-phenylbutanoyl]amino]-4-methyl-N-phenylpentanamide | IC50 | 320.0 [1] |
| (2S)-2-[[(2S)-2-[[(2R)-2-Aminopropanoyl]amino]-4-phenylbutanoyl]amino]-4-methyl-N-phenylpentanamide | Ki | 6.5 [1], 470.0 [2] |
| (2R)-4-(1,3-Dioxobenzo[f]isoindol-2-yl)-2-[[(2S)-4-methyl-1-[[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopentan-2-yl]amino]butanoic acid | IC50 | 90.0 [1], 91.0 [2] |
| (2R)-4-(1,3-Dioxobenzo[f]isoindol-2-yl)-2-[[(2S)-4-methyl-1-[[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopentan-2-yl]amino]butanoic acid | Ki | 20.0 [1] |
| N-Hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride | IC50 | 30.0 [1] |
| Tanomastat | IC50 | 134.0 [1] |
| Tanomastat | Ki | 143.0 [1] |
| (R)-N1-((S)-3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide | IC50 | 470.0 [1] |
| (R)-N1-((S)-3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide | Ki | 310.0 [1] |
| (2S,3R)-N-Hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-prop-2-enylbutanediamide | IC50 | 12.0 [1] |
| Apratastat | IC50 | 10.0 [1] |
| n-[3-(n'-Hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide | IC50 | 30.0 [1] |
| n-[3-(n'-Hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide | Ki | 10.0 [1] |
| Unii-Q56UE7E40Y | IC50 | 3560.0 [1], 4000.0 [2] |
| N-[(Tert-Butoxy)carbonyl]-L-tryptophan | IC50 | 10000.0 [1] |
| N-[(Tert-Butoxy)carbonyl]-L-tryptophan | Ki | 8000.0 [1] |
| (R)-5-(6-Cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamide | IC50 | 10000.0 [1] |
| (R)-N-Hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamide | IC50 | 50.0 [1] |
| cis-2-Aminocyclohexylcarbamoylphosphonic acid | IC50 | 100000.0 [1] |
| (3R)-3-[[(2S)-1-[[(1S)-2-Methoxy-1-phenylethyl]amino]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-6-(3-methyl-4-phenylphenyl)hexanoic acid | IC50 | 23.0 [1] |
| N-[(2S)-1-(4,4-Dimethyl-2,5-dioxoimidazolidin-1-yl)-3-[4-[4-(trifluoromethoxy)phenyl]phenoxy]propan-2-yl]-N-hydroxyformamide | IC50 | 42.0 [1] |
| N-Hydroxy-1-(2-methoxyethyl)-4-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylpiperidine-4-carboxamide | IC50 | 28.7 [1], 29.0 [2] |
| 4-{[1-Methyl-2,4-Dioxo-6-(3-Phenylprop-1-Yn-1-Yl)-1,4-Dihydroquinazolin-3(2h)-Yl]methyl}benzoic Acid | IC50 | 30000.0 [1] |
| (3R,4R)-N-Hydroxy-4-[[4-[[2-(trifluoromethyl)benzimidazol-1-yl]methyl]benzoyl]amino]oxane-3-carboxamide | Ki | 10000.0 [1] |
| N-Hydroxy-4-(4-phenylsulfanylphenyl)sulfonyl-1-prop-2-ynylpiperidine-4-carboxamide | IC50 | 13.0 [1] |
| 4-Benzoyl-N-hydroxy-1-(4-methoxyphenylsulfonyl)piperazine-2-carboxamide | IC50 | 66.0 [1], 66.07 [2] |